Sumitovant Biopharma Ltd., today announced that Urovant Sciences (Nasdaq: UROV), a member of the Sumitovant family of companies, has received U.S. Food and Drug Administration (FDA) approval of its New Drug Application (NDA) for once-daily 75 mg GEMTESA? (vibegron), a beta-3 adrenergic receptor (?3) agonist, for the treatment of overactive bladder (OAB) with symptoms of urge urinary incontinence (UUI), urgency, and urinary frequency in adults. GEMTESA is the first oral branded OAB medication to be approved by the FDA since 2012, and it is the first product approval for Urovant Sciences. ?Sumitovant Biopharma welcomes the first drug approval for Urovant Sciences.? We look forward to providing GEMTESA? to patients with OAB whose needs often remain unsatisfied. ?This is a drug category that has gone without a new branded entrant in eight years so we are pleased to bring a new option to those who can benefit from the advances we have made,? said Myrtle Potter, CEO of Sumitovant Biopharma. ?GEMTESA is the second Sumitovant family product to be approved by the FDA within this past week.? GEMTESA?S approval follows the December 18^th?approval of ORGOVYX^TMfor the treatment of advanced prostate cancer. ?The FDA?s approval of GEMTESA is an important milestone for the tens of millions of patients living with overactive bladder and for Urovant, as it is our first drug approval. We look forward to launching GEMTESA and believe that it will provide a compelling alternative for the many patients suffering from the burden of an overactive bladder. We also remain committed to bringing more new therapies to market that address unmet medical needs of patients suffering from urologic diseases,? said Jim Robinson, president and chief executive officer of Urovant Sciences. ?The clinical data for once-daily 75 mg GEMTESA demonstrated clear efficacy on the key symptoms of OAB, by reducing urinary frequency, urge urinary incontinence, and urgency.? In addition, data specifically showing reduction in urgency episodes are included in the Prescribing Information of GEMTESA, which is unique among currently- available OAB treatments. Urgency episode reduction data are particularly relevant for OAB patients and their health care providers, as they show GEMTESA?s direct impact on a hallmark symptom of the condition,? said Cornelia Haag-Molkenteller, M.D., Ph.D., chief medical officer of Urovant Sciences. ?By successfully treating clinical symptoms, GEMTESA may allow patients to overcome the devastating impact that OAB can have on their daily lives.? GEMTESA is an oral, once-daily tablet containing 75 mg of vibegron, a small-molecule ?3 adrenergic receptor agonist therapy which helps relax the detrusor bladder muscle so that the bladder can hold more urine, thereby reducing symptoms of OAB. ?GEMTESA is the first beta 3-agonist available as a once-daily pill which does not require dose titration,? said David Staskin, MD, clinical trial investigator and a leading urologist with St. Elizabeth?s Medical Center in Boston. ?Notably, GEMTESA did not have any increase in the adverse event of hypertension compared to placebo in the key EMPOWUR study and has no interactions with medications metabolized by CYP2D6, which is important since many common medications are metabolized by CYP2D6.? The FDA?s approval is based on results from an extensive development program involving more than 4,000 OAB patients, including the 12-week double blind, placebo-controlled Phase 3 EMPOWUR study with a dose of 75 mg and the double blind EMPOWUR long term extension study.¹?These data show that treatment with GEMTESA resulted in statistically significant reductions in daily UUI, micturitions, and urgency episodes?and an increase in the volume voided when compared to placebo in EMPOWUR. The most common adverse reactions of GEMTESA from the double blind, placebo-controlled EMPOWUR study in =2% of patients were headache, nasopharyngitis, diarrhea, nausea, and upper respiratory tract infection. GEMTESA demonstrated the same rates for the adverse events of hypertension and increased blood pressure as placebo. Urovant is planning to launch GEMTESA in the United States late in the first quarter of 2021. To learn more about GEMTESA, please visit?GEMTESA.com. About Overactive Bladder OAB is a clinical condition that occurs when the bladder muscle contracts involuntarily. Symptoms may include urinary urgency (the sudden urge to urinate that is difficult to control), urgency incontinence (unintentional loss of urine immediately after an urgent need to urinate), frequent urination (usually eight or more times in 24 hours), and nocturia (waking up more than two times in the night to urinate).² More than 30 million Americans suffer from bothersome symptoms of OAB, which can have a significant impairment on a patient?s day-to-day activities.^3,4 About Urovant Sciences Urovant Sciences is a biopharmaceutical company focused on developing and commercializing innovative therapies for urologic conditions. The Company?s lead product, GEMTESA (vibegron), is an oral, once-daily (75 mg) small molecule beta-3 agonist approved by the U.S. FDA in December 2020 for the treatment of adult patients with overactive bladder (OAB) with symptoms of urge urinary incontinence, urgency and urinary frequency. GEMTESA is also being evaluated for the treatment of OAB in men with benign prostatic hyperplasia (OAB+BPH). The Company?s second product candidate, URO-902, is a novel gene therapy being developed for patients with OAB who have failed oral pharmacologic therapy. Urovant Sciences, a subsidiary of Sumitomo Dainippon Pharma Co., Ltd., intends to develop novel treatments for additional urologic diseases. Learn more about us at?www.urovant.com. About Sumitovant Biopharma Ltd. Sumitovant is a global biopharmaceutical company with offices in New York City and London. Sumitovant is a wholly owned subsidiary of Sumitomo Dainippon Pharma. Sumitovant is the majority shareholder of Myovant Sciences and Urovant Sciences, and wholly owns Enzyvant Therapeutics, Spirovant Sciences, and Altavant Sciences. Sumitovant's promising pipeline is comprised of early-through late-stage investigational medicines across a range of disease areas targeting high unmet need. For further information about Sumitovant, please visit?https://www.sumitovant.com. About Sumitomo Dainippon Pharma Co., Ltd. Sumitomo Dainippon Pharma is among the top-ten listed pharmaceutical companies in Japan, operating globally in major pharmaceutical markets, including Japan, the U.S., China, and the European Union. Sumitomo Dainippon Pharma is based on the 2005 merger between Dainippon Pharmaceutical Co., Ltd., and Sumitomo Pharmaceuticals Co., Ltd. Today, Sumitomo Dainippon Pharma has more than 6,000 employees worldwide. Additional information about Sumitomo Dainippon Pharma is available through its corporate website at?https://www.ds-pharma.com Forward-Looking Statements This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements include all statements that are not historical statements of fact and statements regarding the Company?s intent, belief or expectations and can be identified by words such as ?anticipate,? ?believe,? ?can,? ?continue,? ?could,? ?estimate,? ?expect,? ?intend,? ?likely,? ?may,? ?might,? ?objective,? ?ongoing,? ?plan,? ?potential,? ?predict,? ?project,? ?should,? ?strive,? ?to be,? ?will,? ?would,? or the negative or plural of these words or other similar expressions or variations, although not all forward-looking statements contain these identifying words. In this press release, forward-looking statements include, but are not limited to, statements regarding the impact of vibegron on patients? OAB symptoms and Urovant?s expectations regarding the planned commercial launch and footprint for vibegron. Forward-looking statements are subject to risks and uncertainties that could cause actual results to differ materially and reported results should not be considered as an indication of future performance. These risks and uncertainties include, but are not limited to, risks associated with: the success and cost of Urovant?s efforts to commercialize vibegron; Urovant?s ability to realize the anticipated benefits of the co-promotion agreement with Sunovion in the manner or timeline expected; Urovant?s reliance on Sunovion for the co-promotion and distribution of vibegron and Urovant?s ability to secure alternative access to commercial infrastructure or strategic collaborations for the commercialization or distribution of products if it is unable to continue the relationship with Sunovion; the success, cost, and timing of Urovant?s development activities, including the timing of the initiation and completion of clinical trials and the timing of expected regulatory filings; the clinical utility and potential attributes and benefits of vibegron, including reliance on collaboration partners and the ability to procure additional sources of financing; our intellectual property position, including the ability to identify and in-license or acquire third-party patents and licenses, and associated costs; and other risks and uncertainties listed in the Company?s filings with the United States Securities and Exchange Commission (SEC), including under the heading ?Risk Factors? in the Company?s most recently filed Annual Report on Form 10-K and any subsequent Quarterly Reports on Form 10-Q filed with the SEC, as such risk factors may be amended, supplemented or superseded from time to time by other filings with the SEC. Given these risks and uncertainties, you should not place undue reliance on any forward-looking statements. These forward-looking statements are based on information available to Urovant as of the date of this press release and speak only as of the date of this release. Urovant disclaims any obligation to update these forward-looking statements, except as may be required by law.